Cancer drug discovery targeting histone methyltransferases: an update

Area of Science:

• Oncology
• Epigenetics
• Drug Discovery

Background:

• Epigenetic dysregulation is a key factor in cancer initiation and progression.
• Tumors frequently exhibit both genetic and epigenetic abnormalities.
• Targeting epigenetic proteins offers a novel cancer therapeutic strategy with potential for enhanced efficacy and reduced resistance.

Purpose of the Study:

• To provide an update on drug discovery efforts targeting histone methyl transferases (HMTs).
• To highlight the significance of HMTs as crucial components of the epigenome.
• To review the intense pursuit of HMT inhibitors by the pharmaceutical industry and academia.

Main Methods:

• Review of current drug discovery initiatives focused on key HMTs.
• Analysis of the role of HMTs in epigenetic regulation.
• Assessment of the therapeutic potential of HMT inhibitors in cancer.

Main Results:

• Significant progress has been made in the development of HMT inhibitors.
• Several key HMTs are under intense investigation as therapeutic targets.
• Inhibition of HMTs demonstrates potential to modulate multiple cancer-related signaling pathways.

Conclusions:

• Histone methyl transferase inhibitors represent a promising class of anti-cancer drugs.
• Targeting epigenetic modifications offers a viable strategy for overcoming cancer drug resistance.
• Continued research and development in HMT inhibitor discovery are crucial for advancing cancer treatment.